{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:11:52Z","timestamp":1793938312497,"version":"4.8.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.esmoop.2025.105057","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T07:55:39Z","timestamp":1745481339000},"page":"105057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-7192","authenticated-orcid":false,"given":"S.","family":"Lobo-Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-0364","authenticated-orcid":false,"given":"L.","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4482-3909","authenticated-orcid":false,"given":"T.P.","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-7511","authenticated-orcid":false,"given":"E.","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3870-142X","authenticated-orcid":false,"given":"C.","family":"Dauccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-6054","authenticated-orcid":false,"given":"M.A.","family":"Franzoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-5841","authenticated-orcid":false,"given":"L.","family":"del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"M.","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"E.","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2025.105057_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105057_bib2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105057_bib3","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP Guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105057_bib4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"9793","key":"10.1016\/j.esmoop.2025.105057_bib5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"issue":"10001","key":"10.1016\/j.esmoop.2025.105057_bib6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105057_bib7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105057_bib8","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105057_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101931","volume":"59","author":"Lambertini","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105057_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.43910","article-title":"Chemotherapy-related amenorrhea and quality of life among premenopausal women with breast cancer","volume":"6","author":"Kabirian","year":"2023","journal-title":"JAMA Network Open"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105057_bib11","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2022.07.007","article-title":"ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)","volume":"33","author":"Paluch-Shimon","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105057_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/OP.21.00482","article-title":"Optimal endocrine therapy in premenopausal women: a pragmatic approach to unanswered questions","volume":"18","author":"Sella","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105057_bib13","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105057_bib14","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2025.105057_bib16","article-title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2\u2212 early breast cancer: primary results from the phase III NATALEE trial","volume":"41","author":"Slamon","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105057_bib17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.18.01967","article-title":"Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT","volume":"38","author":"Pagani","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9869","key":"10.1016\/j.esmoop.2025.105057_bib18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"suppl 18","key":"10.1016\/j.esmoop.2025.105057_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105057_bib20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105057_bib21","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105057_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/annonc\/mds330","article-title":"Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole","volume":"24","author":"Goss","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105057_bib23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clbc.2014.04.007","article-title":"Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen","volume":"14","author":"Ruddy","year":"2014","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105057_bib27","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","article-title":"Understanding breast cancer complexity to improve patient outcomes: the St. Gallen International Consensus Conference for the primary therapy of individuals with early breast cancer 2023","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105057_bib28","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105057_bib29","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1200\/JCO.2007.11.6798","article-title":"Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen","volume":"26","author":"Goss","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105057_bib30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2010.34.4010","article-title":"Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover","volume":"30","author":"Jin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105057_bib31","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","article-title":"Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial","volume":"26","author":"Mamounas","year":"2008","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105057_bib32","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jnci\/djm246","article-title":"Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a","volume":"99","author":"Jakesz","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105057_bib33","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/S1470-2045(21)00352-1","article-title":"Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Del Mastro","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(18)30621-1","article-title":"Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology\/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Mamounas","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105057_bib35","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/jnci\/djad078","article-title":"Ten-year update: NRG Oncology\/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer","volume":"115","author":"Mamounas","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105057_bib36","first-page":"GS3","volume":"79","author":"Ohtani","year":"2019","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.esmoop.2025.105057_bib37","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1200\/JCO.22.00577","article-title":"Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial","volume":"41","author":"Iwase","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105057_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101901","article-title":"Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial","volume":"58","author":"Tjan-Heijnen","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/jnci\/djx134","article-title":"Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05)","volume":"110","author":"Blok","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105057_bib40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2104162","article-title":"Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer","volume":"385","author":"Gnant","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-20-2737","article-title":"Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR+ early-stage breast cancer for 10 years of endocrine therapy","volume":"27","author":"Noordhoek","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105057_bib42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1470-2045(17)30715-5","article-title":"Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Colleoni","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105057_bib44","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.annonc.2021.07.017","article-title":"Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy","volume":"32","author":"Jerusalem","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105057_bib45","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41416-019-0435-4","article-title":"Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial","volume":"120","author":"Ribi","year":"2019","journal-title":"Br J Cancer"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2025.105057_bib46","article-title":"Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: a prospective trial","volume":"83","author":"Haddad","year":"2023","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105057_bib47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","article-title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","volume":"22","author":"Mayer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105057_bib48","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105057_bib49","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer\u2014the Penelope-B trial","volume":"39","author":"Loibl","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40487-023-00250-7","article-title":"Adjuvant CDK4\/6 inhibitors for early breast cancer: how to choose wisely?","volume":"12","author":"Agostinetto","year":"2024","journal-title":"Oncol Ther"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2025.105057_bib51","article-title":"LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2\u2212, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes","volume":"34","author":"Harbeck","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105057_bib52","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105057_bib53","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105057_bib55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105057_bib56","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.2011.38.0261","article-title":"Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer","volume":"30","author":"Henry","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105057_bib57","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer","volume":"126","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105057_bib58","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","article-title":"Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer","volume":"22","author":"Franzoi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105057_bib59","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/jamaoncol.2021.1693","article-title":"Association of modifiable risk factors with early discontinuation of adjuvant endocrine therapy: a post hoc analysis of a randomized clinical trial","volume":"7","author":"Yanez","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105057_bib60","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1210\/jc.2002-020396","article-title":"Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women","volume":"87","author":"Rogers","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105057_bib61","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.105057_bib62","article-title":"Adverse effects of adjuvant tamoxifen treatment on bone mineral density in premenopausal breast cancer patients: a systematic review and meta-analysis","volume":"39","author":"Cha","year":"2021","journal-title":"J Clin Oncol"},{"issue":"43","key":"10.1016\/j.esmoop.2025.105057_bib63","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390442","article-title":"Advances in the management of menopausal symptoms, fertility preservation, and bone health for women with breast cancer on endocrine therapy","author":"Lambertini","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jnci\/djx141","article-title":"Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis","volume":"110","author":"Goldvaser","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2025.105057_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103114","article-title":"Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: a systemtic review and meta-analysis","volume":"156","author":"Zhao","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"31","key":"10.1016\/j.esmoop.2025.105057_bib66","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO Clinical Practice Guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105057_bib67","first-page":"96","article-title":"Clinical practice guidelines on postmenopausal osteoporosis: an executive summary and recommendations \u2013update 2019-2020","volume":"11","author":"Meeta","year":"2020","journal-title":"J Midlife Health"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105057_bib68","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib69","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamacardio.2016.3841","article-title":"A population-based study of cardiovascular mortality following early-stage breast cancer","volume":"2","author":"Abdel-Qadir","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib70","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pharmthera.2012.03.007","article-title":"Estrogen and the cardiovascular system","volume":"135","author":"Knowlton","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105057_bib71","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105057_bib72","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdz298","article-title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","volume":"30","author":"Ferreira","year":"2019","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105057_bib73","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.19.01758","article-title":"Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk","volume":"38","author":"Pistilli","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105057_bib74","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.breast.2015.01.010","article-title":"Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients","volume":"24","author":"Kool","year":"2015","journal-title":"Breast"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105057_bib76","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-13-0838","article-title":"Metastasis dormancy in estrogen receptor-positive breast cancer","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/annonc\/mdl334","article-title":"Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen","volume":"18","author":"Kennecke","year":"2007","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105057_bib78","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/jnci\/djt244","article-title":"Factors predicting late recurrence for estrogen receptor\u2013positive breast cancer","volume":"105","author":"Sestak","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-015-0516-0","article-title":"Markers for the identification of late breast cancer recurrence","volume":"17","author":"Sestak","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105057_bib80","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2017.76.4258","article-title":"Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5","volume":"36","author":"Dowsett","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105057_bib81","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105057_bib82","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","article-title":"Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8\u00b71 years median follow-up","volume":"12","author":"Regan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10549-020-06013-6","article-title":"Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer","volume":"186","author":"Richman","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2025.105057_bib85","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.breast.2015.07.002","article-title":"Clinical utility of genetic signatures in selecting adjuvant treatment: risk stratification for early vs. late recurrences","volume":"24","author":"Hayes","year":"2015","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105057_bib86","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s11864-023-01079-y","article-title":"Novel estrogen receptor-targeted agents for breast cancer","volume":"24","author":"Shastry","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2025.105057_bib90","article-title":"Abstract P6-10-06: A preoperative window-of-opportunity study of imlunestrant in estrogen receptor-positive, HER2-negative early breast cancer: results from the EMBER-2 study","volume":"83","author":"Neven","year":"2023","journal-title":"Cancer Res"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105057_bib93","volume":"82","author":"Chien","year":"2022","journal-title":"Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105057_bib94","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.2022.40.16_suppl.528","article-title":"AMEERA-4: A preoperative window-of-opportunity (WOO) study to assess the pharmacodynamic (PD) activity of amcenestrant or letrozole in postmenopausal patients with ER+\/HER2\u2212 primary breast cancer","volume":"40","author":"Campone","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105057_bib95","article-title":"Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)","volume":"40","author":"Meyskens","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105057_bib102","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(23)00268-1","article-title":"Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study","volume":"24","author":"Hurvitz","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105057_bib103","doi-asserted-by":"crossref","first-page":"S1260","DOI":"10.1016\/j.annonc.2023.10.011","article-title":"LBA21 KEYNOTE-756: phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+\/HER2\u2013 breast cancer","volume":"34","author":"Cardoso","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105057_bib104","doi-asserted-by":"crossref","first-page":"S1259","DOI":"10.1016\/j.annonc.2023.10.010","article-title":"LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) \u00b1 NIVO in patients (pts) with high-risk, ER+ HER2\u2212 primary breast cancer (BC)","volume":"34","author":"Loi","year":"2023","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105057_bib105","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.2023.41.16_suppl.3009","article-title":"First-in-human first-in-class phase 1\/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2\u2212 mBC who progressed on prior CDK4\/6 inhibitors and endocrine therapy","volume":"41","author":"Yap","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105057_bib106","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2023.41.16_suppl.3010","article-title":"First-in-human phase 1\/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4\/6 inhibitor resistant HR+\/HER2\u2212 breast cancer","volume":"41","author":"Yap","year":"2023","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.esmoop.2025.105057_bib110","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105057_bib113","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105057_bib114","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1200\/JCO.2012.46.1558","article-title":"Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy","volume":"31","author":"Dowsett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105057_bib115","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/bjc.2013.671","article-title":"The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2\u2212 breast cancer patients","volume":"109","author":"Dubsky","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105057_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100006","article-title":"A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort","volume":"6","author":"Dubsky","year":"2020","journal-title":"ESMO Open"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105057_bib117","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/1078-0432.CCR-13-0804","article-title":"Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105057_bib118","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(13)70387-5","article-title":"Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population","volume":"14","author":"Sgroi","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:46:05Z","timestamp":1757576765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925009263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2059702925009263"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105057","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105057"}}